An observational study in Acute Respiratory Distress Syndrome and Ventilator-Induced Lung Injury, sponsored by Centre Hospitalier de Saint-Brieuc. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Centre Hospitalier de Saint-Brieuc · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Respiratory Distress Syndrome with a site in France — 41 open to participants now, 43 under way, 7 of them phase 3. Respiratory Distress Syndrome · France.
Among the 217 studies in Respiratory Distress Syndrome with a site in France, this one is the 80th largest by enrollment of the 97 observational ones that give a count, is one of 61 that started in 2020, is one of 98 observational ones, and was the 175th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →41 of the 217 studies in Respiratory Distress Syndrome with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Centre Hospitalier de la côte Basque · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 26 · Phase 4 5
First in 2002; this study’s year is marked. 61 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 50 across the 118 interventional studies, 80 across the 97 observational. Of the 145 that completed or were terminated, 4 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 217 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier de Saint-Brieuc is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Centre Hospitalier de Saint-Brieuc has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
12 of the studies in Respiratory Distress Syndrome with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03368092Phase 3University Hospital, Strasbourg, FranceInhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma | 2027-09-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06254313University Hospital, BordeauxThe Role of Cxcr4Hi neutrOPhils in InflueNza | 2026-12 |
| NCT06119516Assistance Publique - Hôpitaux de ParisTranspulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. | 2027-04-04 |
| NCT06807983University Hospital, ToulouseLUng and Cardiac Ultrasound for REspiratory Distress in ElDerly | 2027-05-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 217 studies in Respiratory Distress Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neuromuscular blockade (NMB) is proposed in patients with moderate to severe acute respiratory distress syndrome (ARDS). The supposed benefit of these muscle relaxants could be partly linked to their effects on respiratory mechanics by reducing ventilator induced lung injuries (VILI), especially the so called atelectrauma. Although its monitoring is recommended in clinical practice, data about the depth of NMB necessary for an effective relaxation of the thoracic and diaphragmatic muscles and, therefore, the reduction of the chest wall elastance, are scarce. The investigators hypothesised that complete versus partial NMB can modify respiratory mechanics and its partitioning.
The investigators conducted a prospective study to compare the respiratory mechanics of patients with moderate to severe ARDS according to the NMB depth, using an oesophageal pressure catheter (NutriVent®, Sidam) for transpulmonary pressure (PL) assessment, and facial train of four (TOF) for neuromuscular blockade monitoring. The oesophageal balloon was calibrated according to the method recently described to estimate the individual target volume which is assumed to be more adequate. Each patient was analysed at two different times: deep NMB (TOF = 0) and intermediate to light NMB (TOF > 0). The mechanical ventilation parameters were identical for these two measurements. The primary endpoint was the proportion of patients with expiratory transpulmonary pressure (PLexp) greater than or equal to 0 according to the NMB level, in order to assess the risk of region-dependent atelectasis and alveolar opening/closing injury (atelectrauma). Secondary endpoints included: the impact of the depth of NMB on other partition parameters of respiratory mechanics, and the variability of results according to the type of oesophageal balloon calibration.
The population includes mainly pulmonary ARDS with a predominance of SARS-CoV2 pneumonia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
no intervention
Other: Modulation of the depth of the neuromuscular blockade
Analysis of the respiratory mechanics at two times: * Facial train of four = 0, indicating a deep neuromuscular blockade * Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade
Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0
Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0 according to the level of neuromuscular blockade (%)
Time frame: one day
Inspiratory transpulmonary pressure
Inspiratory transpulmonary pressure according to the level of neuromuscular blockade (cmH20)
Time frame: one day
Respiratory system compliance
Respiratory system compliance according to the level of neuromuscular blockade (ml/cmH20)
Time frame: one day
Chest wall elastance
Chest wall elastance according to the level of neuromuscular blockade (cmH2O/l)
Time frame: one day
Pulmonary elastance
Pulmonary elastance according to the level of neuromuscular blockade (cmH2O/l)
Time frame: one day
Driving pressure
Driving pressure according to the level of neuromuscular blockade (cmH20)
Time frame: one day
Transpulmonary driving pressure
Transpulmonary driving pressure according to the level of neuromuscular blockade (cmH20)
Time frame: one day
Plateau pressure
Plateau pressure according to the level of neuromuscular blockade (cmH20)
Time frame: one day
Oesophageal balloon calibration
Proportion of patients with expiratory transpulmonary pressure greater than or equal to 0 according to the oesophageal balloon calibration volume (%)
Time frame: one day
Plan to share: No
Ran from Feb 2020 to primary completion in Feb 2022, 24 months.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 24 months is close to that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Centre Hospitalier de Saint-Brieuc